4-(2-Methylpropyl)imidazolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-(2-Methylpropyl)imidazolidine
• 英文别名: 4-(2-methylpropyl)imidazolidine
• 化学式: C₇H₁₆N₂
• 分子量: 128.22
• InChiKey: GPEXBQCGPVLXKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
  申请人：AGENSYS, INC.

  公开号：US10894090B2

  公开（公告）日：2021-01-19

  Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

  本文描述了与 191P4D12 蛋白及其变体结合的抗体药物结合物（ADC）。191P4D12 在正常成人组织中具有组织特异性表达，在表 I 所列的癌症中表达异常。因此，本发明的 ADC 为治疗癌症提供了一种治疗组合物。
• Humanized anti-CD79b antibodies and immunoconjugates and methods of use
  申请人：GENENTECH, INC.

  公开号：US10981987B2

  公开（公告）日：2021-04-20

  The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

  本发明涉及用于治疗哺乳动物造血肿瘤的物质组合物，以及使用这些物质组合物治疗造血肿瘤的方法。
• Methylene carbamate linkers for use with targeted-drug conjugates
  申请人：Seagen Inc.

  公开号：US11116847B2

  公开（公告）日：2021-09-14

  The present invention provides Ligand-Drug Conjugates and Drug-Linker Compounds comprising a methylene carbamate unit. The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-Drug Conjugate is comprised of a Self-immolative Assembly Unit having a methylene carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates of the present invention are stable in circulation, yet capable of inflicting cell death once free drug is released from a Conjugate in the vicinity or within tumor cells.

  本发明提供了包含亚甲基氨基甲酸酯单元的配体-药物共轭物和药物-连接体化合物。本发明特别提供了配体-药物共轭物，其中配体-药物共轭物由具有亚甲基氨基甲酸酯单元的自巯基组装单元组成，用于将药物与靶向配体共轭；本发明还提供了配体-药物共轭物的制备和使用方法及其中间体。本发明的配体-药物共轭物在循环中是稳定的，但一旦从肿瘤细胞附近或内部的共轭物中释放出游离药物，就能造成细胞死亡。
• CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：GENENTECH, INC.

  公开号：US20170166635A1

  公开（公告）日：2017-06-15

  Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D) p (I) where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
• ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
  申请人：Genentech, Inc.

  公开号：US20170234883A1

  公开（公告）日：2017-08-17

  Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.